Bibliography
- GAONI Y, MECHOULAM R: Isolation, structure, and partial synthesis of an active constituent of hashish. I Am. Chem. Soc. (1964) 86:1646–1647.
- BARTH F: Cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (1998) 8:301–313.
- DEVANE WA, DYSARZ FA, JOHNSON MR, MELVIN LS, HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. (1988) 34:605–613.
- MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61–65.
- DEVANE WA, HANUS L, BREUER A et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946–1949.
- MECHOULAM R, BEN-SHABAT S, HANUS L et al: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83–90.
- SUGIURA T, KONDO S, SUKAGAWA A et al: 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89–97.
- HANUS L, ABU-LAFI S, FRIDE E et al: 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CBI. receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662–3665.
- PORTER AC, SAUER J-M, KNIERMAN MD et al: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CBI. receptor. Pharmaocol. Exp. The]: (2002) 301:1020–1024.
- CROXFORD JL: Therapeutic potential ofcannabinoids in CNS disease. CNS Drugs (2003) 17:179–202.
- DI MARZO V, FONTANA A, CADAS H et al: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686–691.
- CRAVATT BE GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83–87.
- DEUTSCH DG, GLASER ST, HOWELL JM et al.: The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. Biol. Chem. (2001) 276:6967–6973.
- GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 10:1529–1538.
- ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2002) 12:1475–1489.
- PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Investig. Drugs (2000) 9:1553–1571.
- •This is an excellent review of the cannabinoid field through the year 2000.
- HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev (2002) 54:161–202.
- LANGE JHM, KRUSE CG: Recent advances in CB1 cannabinoid receptor antagonists. Can: Opin. Drug Discov. Dev. (2004) 7:498–506.
- FOWLER CJ, JACOBSON SO: Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins, Leukot. Essent. Fatty Acids (2002) 66:193–200.
- LOPEZ-RODRIGUEZ ML, VISO A, ORTEGA-GUTIERREZ S, FERNANDEZ-RUIZ J, RAMOS JA: Endocannabinoid transporter inhibitors. CLIFF. Med. Chem. Central Nervous System Agents (2002) 2:129–141.
- CRAVATT BE LICHTMAN AH: Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curt: Opin. Chem. Biol. (2003) 7:469–475.
- RINALDI-CARMONA M, BARTH F, HEAULME M et al.: 5R141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–244.
- NAKAMURA-PALACIOS EM, MOERSCHBAECHER JM, BARKER LA: The pharmacology of 5R141716A: a review. CNS Drug Rev. (1999) 5:43–58.
- DYCK B, GOODFELLOW VS, PHILLIPS T et al.: Potent imidazole and triazole CB1 receptor antagonists related to 5R141716. Bioorg. Med. Chem. Lett. (2004) 14:1151–1154.
- LANGE JHM, COOLEN HK, VANSTUIVENBERG HH et al.: Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective cannabinoid receptor antagonists. Med. Chem. (2004) 47:627–643.
- •Further details may be found at [201].
- BELL MR, D'AMBRA TE, KUMAR V et al.: Antinociceptive (aminoalkyl) indoles. Med. Chem. (1991) 34:1099–1110.
- IBRAHIM MM, DENG H, ZVONOK A: Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. NatL Acad. Sci. USA (2003) 100:10529–10533.
- GLASER ST, ABUMRAD NA, FATADE F,KACZOCHA M, STUDHOLME KM, DEUTSCH DG: Evidence against the presence of an anandamide transporter. Proc Natl. Acad. Sci USA (2003) 100:4269–4274.
- CRAVATT BF, DEMAREST K, PATRICELLI MP et al.:Supersensitivity to anandamide and endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA (2001) 98:9371–9376.
- KATHURIA S, GAETANI S, FEGLEY D et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9:76–81.
- BOGER DL, SATO H, LERNER AE et aL: Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. NatL Acad. Sci. USA (2000) 97:5044–5049.
- American College of Cardiology Meeting, New Orleans, March 2004.
- •Details can be found under the Tress Releases' section at [202].
- Analysts' Meetings, Sanofi-Synthelabo, 4 September 2001 and September 2002.
- Company presentation, Sanofi-Synthelabo, 16 February 2004.
- Aventis 2003 Full Year Results Meeting, 5 February 2004, London, UK.
- MALAN TP Jr, IBRAHIM MM, DENG H: CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 93:239–245.
- QUARTHILO A, MATA HP, IBRAHIM MM: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 99:955–960.
Websites
- http://www.solvaypress.com/pressreleases/0„ 18329-2-0,00.htm Solvay Press Office - press release.
- http://en.sanofi- aventis.com/press/ppc_23312.asp?Compon entID23312&SourcePageID23126#4 Sanofi-Aventis press release.